Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Company intelligence / Profile preview
Polarean Imaging has developed and commercialized XENOVIEW®—the first and only FDA-approved hyperpolarized xenon Xe129 MRI contrast agent for visualizing regional lung function. The platform provides non-invasive, radiation-free assessment of ventilation and gas exchange in a single breath-hold. Clinical data presented at major conferences demonstrate its utility across multiple respiratory indications. In June 2025, the FDA expanded XENOVIEW’s indication to include children from six years of age. The company’s technology supports both clinical care and pharmaceutical research trials.
Beyond the preview
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Follow clinical development from trial design and recruitment through results.
Explore licensing agreements, acquisitions, and the assets behind each deal.
Trace financing activity and the investors behind a company’s development.
Compare peer pipelines by target, modality, and therapeutic area.
Explore technology platforms and the patent landscape around relevant assets.
Connect company news and source material to the questions you’re investigating.
See how Gosset can support your research on Polarean Imaging.